|Trade names||Zinacef, Ceftin, others|
|Drug class||Second-generation cephalosporin|
|Intramuscular, intravenous, by mouth|
|Defined daily dose||500 mg (by mouth)|
3,000 mg (by injection)
|Bioavailability||37% on an empty stomach, up to 52% if taken after food|
|Elimination half-life||80 minutes|
|Excretion||Urine 66–100% unchanged|
|Chemical and physical data|
|Molar mass||424.38 g·mol−1|
|3D model (JSmol)|
Cefuroxime, sold under the brand name Zinacef among others, is an antibiotic used to treat and prevent a number of bacterial infections. These include pneumonia, meningitis, otitis media, sepsis, urinary tract infections, and Lyme disease. It is used by mouth or by injection into a vein or muscle.
Common side effects include nausea, diarrhea, allergic reactions, and pain at the site of injection. Serious side effects may include Clostridium difficile infection, anaphylaxis, and Stevens–Johnson syndrome. Use in pregnancy and breastfeeding is believed to be safe. It is a second-generation cephalosporin and works by interfering with a bacteria's ability to make a cell wall resulting in its death.
Cefuroxime was patented in 1971, and approved for medical use in 1977. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. A week of treatment when taken by mouth in the United Kingdom costs the NHS about £18 as of 2019. In the United States, the wholesale cost of this amount is about US$8.50. In 2017, it was the 342nd most commonly prescribed medication in the United States, with more than 800 thousand prescriptions.
As with the other cephalosporins, it is susceptible to beta-lactamase, although as a second-generation variety, it is less so. Hence, it may have greater activity against Haemophilus influenzae, Neisseria gonorrhoeae, and Lyme disease. Unlike other second-generation cephalosporins, cefuroxime can cross the blood-brain barrier.
Cefuroxime is generally well tolerated, and its side effects are usually transient. If ingested after food, this antibiotic is both better absorbed and less likely to cause its most common side effects of diarrhea, nausea, vomiting, headaches/migraines, dizziness, and abdominal pain compared to most antibiotics in its class.[medical citation needed]
Although a widely stated cross-allergic risk of about 10% exists between cephalosporins and penicillin, recent[when?] assessments have shown no increased risk for a cross-allergic reaction for cefuroxime and several other second-generation or later cephalosporins.
In the U.S. it is marketed as Zinacef by Covis Pharmaceuticals since the company acquired the U.S. rights to the product from GSK. GSK had continued marketing a pediatric oral suspension as Ceftin; however, this presentation was discontinued as of 24 June 2017.
In Bangladesh, it is available as Rofurox by Radiant, Kilbac by Incepta and Xorimax by Sandoz. In India, it is available as Ceftum in tablet form and Supacef in injection form by GSK. In Poland, it is available as Zamur by Mepha, subsidiary of Teva Pharmaceutical Industries. In Australia, the "first generic" form of Cefuroxime axetil, Pharmacor Cefuroxime (tablets) from Pharmacor Pty Ltd, was registered on 27 March 2017, by the Therapeutic Goods Administration. Cefuroxime axetil is also available (in two strengths) as granules for oral suspension from Aspen Pharmacare Australia Pty Ltd under the brand name Zinnat cefuroxime.
Society and culture
In the United States, the wholesale cost of this amount is about US$8.50. In 2017, it was the 342nd most commonly prescribed medication in the United States, with more than 800 thousand prescriptions.. A week of treatment when taken by mouth in the United Kingdom costs the NHS about £18 as of 2019.
- "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 9 September 2020. CS1 maint: discouraged parameter (link)
- British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 518. ISBN 9780857113382.
- "Cefuroxime Sodium Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 22 March 2019. CS1 maint: discouraged parameter (link)
- "Cefuroxime Use During Pregnancy". Drugs.com. Retrieved 3 March 2019. CS1 maint: discouraged parameter (link)
- Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 493. ISBN 9783527607495.
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019. CS1 maint: discouraged parameter (link)
- "Cefuroxime - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.
- Root, Richard K.; Waldvogel, Francis; Corey, Lawrence; Stamm, Walter E. (1999). Clinical Infectious Diseases: A Practical Approach. Oxford University Press. p. 259. ISBN 9780195081039.
- Gower EW, Lindsley K, Tulenko SE, Nanji AA, Leyngold I, McDonnell PJ (2017). "Perioperative antibiotics for prevention of acute endophthalmitis after cataract surgery". Cochrane Database Syst Rev. 2: CD006364. doi:10.1002/14651858.CD006364.pub3. PMC 5375161. PMID 28192644.
- Pichichero ME (2006). "Cephalosporins can be prescribed safely for penicillin-allergic patients" (PDF). The Journal of family practice. 55 (2): 106–12. PMID 16451776. Archived from the original (PDF) on 24 February 2012. CS1 maint: discouraged parameter (link)
- Walter Sneader. "Drug Discovery: History".
- "FDA Drug Shortages". Food and Drug Administration (FDA). 20 March 2018.
- "GlaxoSmithKline Pharmaceuticals Limited – Prescription Medicines – Anti-Infective". Gsk-india.com. 26 March 2013.
- "Charakterystyka produktu lecznicznego" (PDF). Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych. 12 November 2015.
- "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". TGA. Therapeutic Goods Administration. Retrieved 30 July 2018. CS1 maint: discouraged parameter (link)
- "ARTG ID 81301". TGA. Therapeutic Goods Administration. Retrieved 30 July 2018. CS1 maint: discouraged parameter (link)
- "Cefuroxime". Drug Information Portal. U.S. National Library of Medicine.